#1 Clinical Trials Search in Europe

Study on Bone Marrow Cells and Saline for Treating Severe Limb Ischemia in Patients at High Risk of Amputation

2 1 1 1

What is this study about?

This clinical trial is focused on studying a condition known as chronic limb ischemia, which is a severe blockage in the arteries of the lower extremities that significantly reduces blood flow. This condition can lead to pain and increase the risk of amputation. The study is particularly concerned with patients who are at high risk of losing a limb due to this condition. The treatment being tested involves using autologous bone marrow-derived cells, which are cells taken from the patient’s own bone marrow, to see if they can help improve blood flow and reduce the risk of amputation.

The purpose of the study is to evaluate the safety and effectiveness of this treatment. Researchers aim to see if the treatment can decrease pain, improve the function of the affected limb, and delay or prevent amputation. The study will also explore the best way to administer the treatment. Participants will receive the treatment through an injection directly into the artery, and the effects will be monitored over time to assess any changes in their condition.

Throughout the study, participants will be observed for any side effects and improvements in their condition. The goal is to determine if this new approach can offer a viable option for those who have no other surgical or medical options available. The study will help to understand if using the patient’s own cells can promote healing and improve quality of life for individuals with severe chronic limb ischemia.

1 initial assessment

The patient undergoes an initial assessment to confirm eligibility for the trial. This includes verifying age, medical condition, and other health parameters.

Eligibility criteria include being between 18 and 90 years old, having advanced chronic ischemia with a risk of limb amputation, and no surgical or endovascular revascularization options.

2 informed consent

The patient is required to sign an informed consent form, acknowledging understanding of the trial’s purpose and procedures.

3 treatment administration

The treatment involves the use of autologous bone marrow-derived cells, administered intra-arterially.

The administration aims to evaluate safety and efficacy in reducing pain, improving function, and delaying or preventing amputation.

4 monitoring and follow-up

The patient is monitored for any adverse effects and improvements in their condition.

Primary endpoints include changes in anatomical and functional measures, such as the ankle/brachial index and ischemic ulcer size.

5 trial completion

The trial is estimated to conclude by April 30, 2025.

Final assessments are conducted to evaluate the overall outcomes of the treatment.

Who Can Join the Study?

  • The patient must be between 18 and 90 years old.
  • The patient must have advanced chronic ischemia, which is a condition where blood flow to the limbs is severely reduced, classified as Fontaine III-IV or Rutherford IV-V. This means the patient is at risk of losing at least one limb.
  • The patient must have no option for surgical or endovascular revascularization, meaning there are no available procedures to restore blood flow to the affected limb.
  • The patient must have a life expectancy of more than 2 years.
  • The patient must have normal blood parameters, which include:
    • Leukocytes (a type of white blood cell) must be 3000 or more.
    • Neutrophils (another type of white blood cell) must be 1500 or more.
    • Platelets (cells that help with blood clotting) must be 140,000 or more.
  • The patient must provide signed informed consent, which means they agree to participate in the study after being informed about it.

Who Cannot Join the Study?

  • Patients with a condition called advanced chronic ischemia in the most severe stages (Fontaine III-IV class and Rutherford IV-V) are not eligible. This condition involves poor blood flow to the limbs, which can lead to a risk of losing a limb.
  • Patients who are at risk of having at least one limb amputated cannot participate.
  • Individuals who are not within the specified age range for the study are excluded. The study is open to certain age groups only.
  • Both men and women can participate, but those who do not meet the gender criteria are excluded.
  • People who are considered part of a vulnerable population, which means they might need special protection or care, are not eligible for this study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not yet recruiting
05.05.2021

Trial locations

Investigated drugs:

Autologous Bone Marrow Derived Cells: These are special cells taken from a patient’s own bone marrow. They are used in this trial to treat chronic limb ischemia, a condition where blood flow to the limbs is reduced, increasing the risk of amputation. The goal is to see if these cells can help improve blood flow, reduce pain, and prevent the need for amputation.

Investigated diseases:

Chronic Limb Ischemia – This condition occurs when there is a severe reduction in blood flow to the limbs, often due to narrowed or blocked arteries. It typically progresses through stages, starting with pain during exercise and advancing to pain at rest. In severe cases, it can lead to tissue damage and ulcers due to the lack of oxygen and nutrients. The condition is classified into stages, such as Fontaine III-IV and Rutherford IV-V, indicating the severity of symptoms and risk of complications. Chronic limb ischemia can significantly impact mobility and quality of life, as it may lead to the risk of amputation if not managed properly.

Trial ID:
2025-520937-22-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • A study to evaluate the efficacy and safety of orforglipron in patients with peripheral artery disease

    Recruiting

    3 1
    Investigated diseases:
    France The Netherlands Poland Slovakia